FDA approves zanubrutinib for Waldenström’s macroglobulinemia

Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström's macroglobulinemia (WM). August 31, 2021.  More information: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA